Sunday, August 23, 2026

6 days
Enhertu (DESTINY‑Lung04) improves PFS in HER2‑mutant lung cancer (4)


In Detail Full day, Sunday, August 23, 2026, Timezone: America/Chicago

5 Surprising Signs of Aging

Jancee Dunn / nytimes - Hint: You may need to buy new shoes.

AI Summary: Phase III DESTINY‑Lung04 data show trastuzumab deruxtecan (Enhertu) significantly prolongs progression‑free survival as first‑line therapy for HER2‑mutant non‑small cell lung cancer. Investigators hail the efficacy signal, but oncologists caution that longer follow‑up is needed to determine whether the PFS benefit will translate into overall survival advantage.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials #genetics
Pharmaceuticals RSSBiotech RSSDrug Development RSSOncology RSSCancer Research RSSClinical Trials RSSGenetics RSS

5 Surprising Signs of Aging

9 days / nytimes / Jancee Dunn

Alison Dziarmaga Shares Positive Phase III DESTINY-Lung04 Trial Results in HER2-Mutant NSCLC

10 days / oncodaily

David Gandara: DESTINY-Lung04 Phase III Results: Will Improved PFS Translate to Overall Survival?

11 days / oncodaily

DESTINY-Lung04: Enhertu Improves First-Line PFS in HER2-Mutant NSCLC

12 days / oncodaily

Back to Top / Sun, August 23, 2026, 11:21 am / permalink 29216 / 4 stories in 6 days /







StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Nutrition, None, Weight Loss, Infectious Disease and look for the RSS link.

More StackHealth



Back to Top
↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.